Jocelyn Chan

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Georgia Hatzivassiliou, Jacob R. Haling, Huifen Chen et al. · Nature · 2013 · 317 citations

Oncology, Medicine, Receptor Tyrosine Kinase +6

Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition

Klaus P. Hoeflich, Mark Merchant, Christine Orr et al. · Cancer Research · 2011 · 242 citations · Full text

Chemoprevention Strategy, Apoptosis, Cell Death +19

Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events

Jinfeng Liu, William Lee, Zhaoshi Jiang et al. · Genome Research · 2012 · 206 citations · Full text

Engineering, Genetics, Additional Exon +20

Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression

Klaus P. Hoeflich, Sylvia Herter, Janet Tien et al. · Cancer Research · 2009 · 172 citations · Full text

Tumor Biology, Melanoma Tumors, Oncogenic Activation +14

Discovery of (<i>S</i>)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1<i>H</i>-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1<i>H</i>)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development

James F. Blake, Michael Burkard, Jocelyn Chan et al. · Journal of Medicinal Chemistry · 2016 · 156 citations · Full text

Erk Kinase Activity, Cellular Pharmacology, Tumor Biology +20